Stocks making the biggest moves midday: Spotify, General Motors, Royal Caribbean, Pfizer and more
Check out the companies making headlines in midday trading. Spotify — Shares of the music streaming company lost 3.8% on the back of disappointing results. Spotify reported first-quarter operating income of 509 million euros, while analysts polled by FactSet expected 519.9 million euros. Spotify's revenue of 4.2 billion euros was in line with estimates, while its monthly active users of 678 million met the company's guidance. General Motors — Shares ticked down 2% after the automaker said it was reconsidering its full-year outlook due to concerns over tariffs and macroeconomic uncertainty. That admission overshadowed a better-than-expected earnings report for first quarter. Hims & Hers Health — Shares of the telehealth company soared 26% following news that Novo Nordisk will offer its weight loss drug Wegovy through Hims' platform, as well as Ro and LifeMD. Royal Caribbean — The stock slipped nearly 2% after the cruise operator reported mixed results for its first quarter. Adjusted earnings were $2.71 per share, topping the $2.55 a share expected from analysts polled by FactSet. Revenue came in at $4 billion, just shy of the $4.01 billion consensus estimate. Deutsche Bank — Shares of the German bank jumped 3.5%. The lender saw its profit surge 39% in the first quarter, in addition to a 10% gain in net revenue for the firm's investment banking segment. Regeneron — The pharmaceutical company slid 8.8% following a first-quarter earnings miss and a slashed full-year outlook for gross margin. Regeneron earned an adjusted $8.22 per share on $3.03 billion in revenue, while analysts surveyed by FactSet forecasted $8.62 per share and $3.25 billion of revenue. SoFi Technologies — The fintech bank added 1% after first-quarter net revenue topped expectations. SoFi posted an adjusted $770.7 million, beating the consensus estimate of $739 million from analysts surveyed by FactSet. Waste Management — The garbage collection and recycling stock dipped about 1% after first-quarter revenue came in lighter than expected. Waste Management reported $6.02 billion in revenue, below the $6.11 billion projected by analysts, according to FactSet. Pfizer — Shares popped 3% after the drug maker announced an expansion of its cost-cutting initiatives and said its first-quarter profit came in ahead of Wall Street expectations. However, Pfizer posted declining sales due to further slides in Covid vaccine revenue. While Pfizer held its 2025 guidance steady, the company said it was not yet sure how tariffs would impact the business. Honeywell — The manufacturing and technology company rallied 4.5% on better-than-expected earnings for the first quarter. Honeywell earned $2.51 per share, excluding items, and $9.82 billion in revenue, while analysts penciled in $2.21 per share and revenue at $9.59 billion, per FactSet. BP — U.S. shares of the British oil giant retreated nearly 3% after net profit missed the Street's prediction. BP posted $1.38 billion in underlying replacement cost profit — a proxy for net profit — in the first quarter, while analysts surveyed by LSEG expected $1.6 billion. NXP Semiconductors — The chip stock tumbled 8%. While the company beat expectations on both lines, the company announced Rafael Sotomayor will replace Kurt Sievers as CEO. Leggett & Platt — Shares surged 27% after the bedding products manufacturer reiterated its full-year outlook. Though executives said they should see a net benefit from tariffs, but the company cautioned that the duties could weigh on consumer confidence and demand, and could also push inflation up. Sherwin-Williams — The panting and coating company advanced about 5% after posting better-than-expected earnings per share and reaffirming full-year guidance. However, Sherman-Williams recorded $5.31 billion in revenue, missing the $5.40 billion consensus estimate from FactSet. Welltower — Shares of the health care real estate investment trust rose 1.5% on better-than-anticipated first-quarter results. Welltower recorded $2.42 billion in revenue, while analysts polled by FactSet estimated $2.34 billion. Woodward — The manufacturing stock added 2% after posting fiscal second-quarter adjusted earnings of $1.69 per share on revenue of $884 million. Analysts polled by FactSet had expected earnings of $1.46 per share and revenue of $835.2 million. Woodward also raised the lower end of both its full-year earnings and revenue guidance ranges. Universal Health Services — The health-care facility operator lost nearly 2% after posting $4.10 billion in first-quarter revenue, missing the FactSet consensus forecast of $4.15 billion. But the company earned $4.84 per share, excluding items, beating the Street's prediction of $4.35 per share. Cadence Design Systems — The electronics design stock advanced 3.9%. The company posted first-quarter earnings of $1.57 per share, excluding items, surpassing the LSEG consensus estimate of $1.49 per share. Cadence's revenue for the quarter came in line with expectations at $1.24 billion. — CNBC's Michelle Fox, Hakyung Kim, Pia Singh, Lisa Han, Jesse Pound and Sarah Min contributed reporting
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
America's Car-Mart (NASDAQ:CRMT) Delivers Strong Q1 Numbers, Stock Soars
Used-car retailer America's Car-Mart (NASDAQ:CRMT) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $370.2 million. Its GAAP profit of $1.26 per share was 46.1% above analysts' consensus estimates. Is now the time to buy America's Car-Mart? Find out in our full research report. Revenue: $370.2 million vs analyst estimates of $343.5 million (1.9% year-on-year growth, 7.8% beat) EPS (GAAP): $1.26 vs analyst estimates of $0.86 (46.1% beat) Adjusted EBITDA: $33.92 million vs analyst estimates of $25.12 million (9.2% margin, 35.1% beat) Operating Margin: 8.6%, up from 5.1% in the same quarter last year Free Cash Flow was $18.44 million, up from -$12.01 million in the same quarter last year Locations: 154 at quarter end, in line with the same quarter last year Same-Store Sales fell 3.9% year on year (-5.3% in the same quarter last year) Market Capitalization: $477 million With a strong presence in the Southern and Central US, America's Car-Mart (NASDAQ:CRMT) sells used cars to budget-conscious consumers. Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. With $1.39 billion in revenue over the past 12 months, America's Car-Mart is a small retailer, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with suppliers. On the bright side, it can grow faster because it has more white space to build new stores. As you can see below, America's Car-Mart grew its sales at a solid 13% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) despite not opening many new stores. This quarter, America's Car-Mart reported modest year-on-year revenue growth of 1.9% but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, a deceleration versus the last six years. Still, this projection is healthy and implies the market sees success for its products. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. America's Car-Mart listed 154 locations in the latest quarter and has kept its store count flat over the last two years while other consumer retail businesses have opted for growth. When a retailer keeps its store footprint steady, it usually means demand is stable and it's focusing on operational efficiency to increase profitability. The change in a company's store base only tells one side of the story. The other is the performance of its existing locations and e-commerce sales, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales provides a deeper understanding of this issue because it measures organic growth at brick-and-mortar shops for at least a year. America's Car-Mart's demand has been shrinking over the last two years as its same-store sales have averaged 2.7% annual declines. This performance isn't ideal, and we'd be concerned if America's Car-Mart starts opening new stores to artificially boost revenue growth. In the latest quarter, America's Car-Mart's same-store sales fell by 3.9% year on year. This decrease represents a further deceleration from its historical levels. We hope the business can get back on track. We were impressed by how significantly America's Car-Mart blew past analysts' revenue, EPS, and adjusted operating income expectations this quarter. Zooming out, we think this quarter featured some important positives. The stock traded up 6.9% to $61.75 immediately following the results. America's Car-Mart may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. The research collaboration and exclusive worldwide license agreement will see Deep Apple tasked with discovering and optimising drug candidates directed at a non-incretin G protein-coupled receptor target. Novo Nordisk will then have the option to develop, manufacture, and commercialise the resulting compounds and products in all indications. Duties will be transferred before the start of clinical trials, though both companies will collaborate on the research plan. The breakdown of the $812m figure was not disclosed, though it is constituted of an upfront payment, research costs, and milestone payments. Deep Apple is also in line to receive royalties on sales on any products borne from the partnership that reach market. The agreement marks a significant moment for Novo Nordisk, as it channels substantial resources into research that is not centred around incretins. The drugmaker's flagship drug semaglutide, known under the brand names Wegovy and Ozempic for obesity and type 2 diabetes treatment respectively, targets the glucagon-like peptide-1 receptor (GLP-1R), a key component of the incretin system. Eli Lilly's rival drug tirzepatide, known under the brand names Mounjaro and Zepbound for weight loss and type 2 diabetes respectively, is a dual incretin – targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Novo Nordisk and Deep Apple have not disclosed the name of their intended target, saying only that is a 'non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple's platform.' Deep Apple's drug discovery platform combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM). 'Novo Nordisk is developing a range of potential oral medicines for cardiometabolic diseases across modalities and targets, as we know that people living with these diseases have different needs and preferences,' said Jacob Sten Petersen, senior vice president of diabetes, obesity and MASH therapeutic area at Novo Nordisk. 'We look forward to exploring this novel target further based on Deep Apple's AI-powered platform and expertise in small molecule drug discovery,' Petersen added. Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding. The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Deep Apple is the latest biotech Novo Nordisk has tapped in efforts to regain market share in the cardiometabolic disease market. Eli Lilly's tirzepatide is outpacing semaglutide in terms of sales, leading to declining share prices for the Danish big pharma. Novo Nordisk's new candidate, CagriSema, was hyped as a successor to semaglutide only to produce underwhelming results in a Phase III trial. Incidentally, the company listed two new trials on this week as it continues to evaluate the efficacy of the drug. Struggles at the drugmaker culminated in long-time CEO Lars Fruergaard Jørgensen stepping down in May 2025. Other deals initiated by Novo Nordisk in 2025 include a $345m pact with Gensaic, $50m invested in Variant Bio, and a potential $2bn deal with United Laboratories for a GLP-1/GIP/glucagon triple receptor agonist. "Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
